Presentation prepared for Ag Innovation Showcase

1
Presentation prepared forAg Innovation Showcase
John L. McIntyre, Ph.D., President CEO Peter S.
Carlson, Ph.D., Chief Scientist May 19, 2009
2
Venomix, Inc.

• Developing the next generation of insecticide
  products for the environmentally conscious 21st
  century

3
Venomix is the only

• agricultural biotechnology company that is
  developing proprietary insecticides at are
  designed to compete directly in the marketplace
  against current commercial synthetic chemical
  insecticide products

4
Why?

• Four molecular targets account for the activity
  of essentially all major current insecticides
• Two sites account for 75 of current products
• Because of the continued targeting of these
  active sites insect resistance is now rampant
• Resistance to new insecticides that target
  old sites
• 500 species resistant to at least one insecticide
• Many insecticides have undesirable environmental
  and toxicological profiles
• May be toxic to man
• Several major classes of widely used insecticides
  under intense regulatory scrutiny

5
The Insecticide Industry

• Venomix brings new opportunities and innovation
  to the insecticide industry
• Venomix is able to deliver proprietary green
  insecticides with greatly lowered regulatory
  barriers
• Small synthetic chemical molecule insecticides
  will be developed along with peptide insecticides
  and GMO plants

6
(No Transcript)
7
rpHPLC fractionation of H. versuta venom leads to
identification of a family of insect-selective
toxins, the ?-ACTX-1s
8
Summary of Venomix Technology Platform

• Orally-active insect-specific peptide toxins
• New ion channel targets for insecticide discovery
• The first new insecticide targets validated in
  more than a decade
• Mapped pharmacophores for rational
  synthesis/design
• Peptide toxin transgenes for expression in crops
• Not toxic to animals
• Complete IP coverage of the
• technology
• Rapid US EPA registration
• Toxins considered a microbial by EPA for
  regulatory purposes

9
Current Product Opportunities
10
Emergence of the Venomix Technology

• Since start-up in April 2007 Venomix has achieved
  or exceeded every technical milestone
• Oral and topical activity of the toxin peptide
• Spray-on product developed
• Yeast based production system
• Define effective formulations of the peptide
• Field and large-scale performance trials of the
  toxin peptide designed and underway
• Multi-site vegetable (CA, FL, NY)
• Mosquito, house fly, cockroach
• Synthetic chemical mimics of the toxin peptide
  pharmacophore
• Rational design chemistry
• in silico chemical modeling
• Expression of insecticidal characteristics in
  transformed plants

11
(No Transcript)
12
Small Molecule Discovery
Avail. Small Molecules (millions)
4,500 virtual hits
Peptide pharmacophore
Computational model For in silico screening
Hits
Clusters
1 3uM 4 10-100uM
SAR
1,500 unique drug like Screened compounds
13
Transgenic PlantsManduca sexta Foliar Bioassay
(90 hrs.)
Wild-type Control Tobacco (5 plants)
T1 Homo/Hetero Segregating Line, 25-08 (6
plants)
Omega-ACTX-Hv1a, Plant Vector TDNA (3.77kb)
14
Market Size
15
Venomix Business Strategy

• Direct Sales
• High-value specialty crops in North America
• Partnerships and Licenses
• Agriculture large acreage commodity crops
• Animal health
• Non-crop markets
• International markets
• GMOs seeds and other
• Pharmaceuticals and other pesticides

16
Venomix Partners

• Equity
• SWMF Life Science Fund
• Open Prairie Ventures II
• Michigan PreSeed Venture Fund
• Strategic
• Chemtura Corporation
• More opportunities today for product development
  than there were when we initiated this project.

Source Paul Thomson, Director, New Business
Development Technology, Chemtura
Corporation
17
Venomix 5-Year Plan
18
Venomix Ready for an Exit (4-6 Years)

• Diverse portfolio of novel insecticide products
• Significant product sales with high gross margins
• Tools for continued pipeline of new products
• Novel insecticidal peptides
• Pharmacophores characterized
• Novel molecular target sites
• No mammalian toxicity
• Strategic industry alliances

19
Peter S. Carlson, Ph.D., Chief Scientist Phone 30
1-233-4462 4717 Campus Drive, Suite 1200,
Kalamazoo, MI 49008 Website www.venomix.net